JP2016533373A5 - - Google Patents

Download PDF

Info

Publication number
JP2016533373A5
JP2016533373A5 JP2016524100A JP2016524100A JP2016533373A5 JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5 JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tumor
pancreatic cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533373A (ja
JP6525983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/050952 external-priority patent/WO2015054781A1/en
Publication of JP2016533373A publication Critical patent/JP2016533373A/ja
Publication of JP2016533373A5 publication Critical patent/JP2016533373A5/ja
Application granted granted Critical
Publication of JP6525983B2 publication Critical patent/JP6525983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524100A 2013-10-18 2014-10-03 膵癌の治療法 Expired - Fee Related JP6525983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892887P 2013-10-18 2013-10-18
US61/892,887 2013-10-18
PCT/CA2014/050952 WO2015054781A1 (en) 2013-10-18 2014-10-03 Treatment for pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2016533373A JP2016533373A (ja) 2016-10-27
JP2016533373A5 true JP2016533373A5 (enExample) 2017-11-09
JP6525983B2 JP6525983B2 (ja) 2019-06-05

Family

ID=52827497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524100A Expired - Fee Related JP6525983B2 (ja) 2013-10-18 2014-10-03 膵癌の治療法

Country Status (13)

Country Link
US (1) US9642856B2 (enExample)
EP (1) EP3057593B1 (enExample)
JP (1) JP6525983B2 (enExample)
KR (1) KR102195494B1 (enExample)
CN (1) CN105764515B (enExample)
AU (1) AU2014336917B2 (enExample)
CA (1) CA2927612C (enExample)
EA (1) EA030089B1 (enExample)
ES (1) ES2908200T3 (enExample)
IL (1) IL245037B (enExample)
MX (1) MX357763B (enExample)
SG (1) SG11201602882VA (enExample)
WO (1) WO2015054781A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
HRP20190564T1 (hr) 2013-10-18 2019-05-17 University Health Network Sol i kristalni oblici inhibitora plk-4
CN111225670A (zh) * 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU4155697A (en) 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AU5468499A (en) 1998-08-04 2000-02-28 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
CA2368041A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU2001268154A1 (en) 2000-06-02 2001-12-17 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
EP1696906A1 (en) 2003-12-16 2006-09-06 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
US20090209537A1 (en) * 2006-06-30 2009-08-20 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitors
CA2690567A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Rsk1阻害作用を有する新規スピロインダン誘導体
JP2011506494A (ja) 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
CN102014900B (zh) 2008-03-11 2014-04-02 大学健康网络 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Jfeスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
PT2556071T (pt) * 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
SG11201908865WA (en) 2017-06-29 2019-10-30 Quanticision Diagnostics Inc Apparatus and method for absolute quantification of biomarkers for solid tumor diagnosis

Similar Documents

Publication Publication Date Title
Catalano et al. Gastric cancer
Nielsen et al. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan+/− targeted therapy
KR102490334B1 (ko) 암 치료용 아젤니디핀 약학 조성물의 새로운 적응증
JP2016538344A5 (enExample)
JP2018529656A5 (enExample)
JP2019523214A5 (enExample)
JP2016533366A5 (enExample)
JP2015513919A5 (enExample)
JP2017517520A5 (enExample)
JP2016515561A5 (enExample)
AR094849A1 (es) Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
JP2016501221A5 (enExample)
JP2016528162A5 (enExample)
JP2016506413A5 (enExample)
JP2015522522A5 (enExample)
JP2018513155A5 (enExample)
JP2019506392A5 (enExample)
JP2017516827A5 (enExample)
JP2019517507A5 (enExample)
JP2016529236A5 (enExample)
JP2016540726A5 (enExample)
JP2016522188A5 (enExample)
JP2011500841A5 (enExample)
JP2016513722A5 (enExample)